SCHEMBL6344210

SCHEMBL6344210

COc1cc2nc(CC(C)=O)oc(=O)c2cc1OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.60
KMT2A Q03164 2/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
HSD17B10 Q99714 3/20 0.56
LMNA P02545 1/20 0.56
POLB P06746 1/20 0.55
ELANE P08246 4/20 0.54
ALDH1A1 P00352 2/20 0.54
HTT P42858 1/20 0.54
KLK7 P49862 6/20 0.48
KLK14 Q9P0G3 6/20 0.48
KLK5 Q9Y337 6/20 0.48
CTSG P08311 5/20 0.48
CTRC Q99895 2/20 0.48
MAPT P10636 1/20 0.48
HPGD P15428 1/20 0.48
PTK2B Q14289 1/20 0.48
MEN1 O00255 1/20 0.48
MAPK1 P28482 1/20 0.47
C1R P00736 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11710939 0.76 KDM4E (0.54) KDM4EKMT2ASMN1; SMN2LMNAELANE
SCHEMBL6349049 0.76 ELANE (0.59) KDM4EKMT2ALMNAPOLBELANE
SCHEMBL6339961 0.76 KDM4E (0.46) KDM4EKMT2ASMN1; SMN2HSD17B10ELANE
SCHEMBL7098826 0.76 KDM4E (0.79) KDM4EKMT2ASMN1; SMN2HSD17B10LMNA
SCHEMBL6350945 0.75 C1R (0.46) KDM4ELMNAELANEALDH1A1C1R
SCHEMBL12360274 0.74 KDM4E (0.65) KDM4EKMT2ASMN1; SMN2HSD17B10LMNA
SCHEMBL6341584 0.74 ELANE (0.44) KDM4EKMT2ASMN1; SMN2POLBELANE
SCHEMBL5370167 0.74 ELANE (0.68) KMT2AELANEMEN1C1R
SCHEMBL10657011 0.71 ELANE (0.68) KDM4EKMT2ASMN1; SMN2HSD17B10POLB
SCHEMBL22952908 0.71 KLK7 (0.67) KDM4EKMT2ASMN1; SMN2HSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949648-B2 Condensed pyrazole derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-09-27 US disclosed
US-20030187014-A1 Condensed pyrazole derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-10-02 US disclosed
EP-1270572-A1 CONDENSED PYRAZOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187014-A1 Condensed pyrazole derivatives, process for producing the same and use thereof PTGS1, PTGIS, IL5 KDM4E 1741/4885KMT2A 3347/4885SMN1; SMN2 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.